



## Editorial

# Cancer Screening and Prevention Launches Its Inaugural Issue



Ken H. Young<sup>1</sup> and Zhao-Shen Li<sup>2\*</sup> 

<sup>1</sup>Division of Hematopathology, Duke University Medical Center and Cancer Institute, Durham, USA; <sup>2</sup>Department of Gastroenterology, National Clinical Research Center for Digestive Diseases, Changhai Hospital, Naval Medical University, Shanghai, China

Received: October 26, 2022 | Revised: November 16, 2022 | Accepted: November 25, 2022 | Published: November 29, 2022



Prof. Zhao-Shen Li



Prof. Ken H. Young

On behalf of the Editorial Board, we are delighted to announce the publication of the inaugural issue of *Cancer Screening and Prevention* (CSP).

Over the past 20 years, there has been an increase in cancer incidence and mortality in China, and the major reasons are the lack of awareness of the importance of the early diagnosis and treatment of cancer in the general population, and the lack of effective screening methods and preventive measures in China.<sup>1</sup> Consequently, most patients are diagnosed with cancer at the advanced stage, making the treatment in China far less effective than that in

Western countries. Under the active advocacy and promotion of several academicians,<sup>2</sup> the Chinese government has been taking action in cancer prevention since 2019,<sup>3</sup> which includes the establishment and implementation of strategic programs for the screening, prevention and early diagnosis of cancers, and the increase in funding for cancer research. Despite the great achievements accomplished over the past years, there is still a long way to go to catch up the Western countries, in terms of the screening, prevention, early diagnosis and treatment of cancers. With the continuous and strong support from the Chinese government, both in funding and policy, research activities for searching novel screening and diagnostic methods, and effective preventive and therapeutic modalities for cancers continue to increase in China.

CSP was established to accommodate and showcase the high-quality outputs of research activities in China, and promote international academic communications. CSP publishes epidemiological, translational, and clinical studies related to cancer screening and prevention, including, but not limited to, research on epidemiology, screening, early diagnosis, prevention, biomarkers, novel

**Abbreviations:** CSP, *Cancer Screening and Prevention*.

**\*Correspondence to:** Zhao-Shen Li, Department of Gastroenterology, National Clinical Research Center for Digestive Diseases, Changhai Hospital, Naval Medical University, Shanghai 200433, China. ORCID: <https://orcid.org/0000-0002-1963-2070>. E-mail: [li.zhaoshen@hotmail.com](mailto:li.zhaoshen@hotmail.com)

**How to cite this article:** Young KH, Li ZS. *Cancer Screening and Prevention* Launches Its Inaugural Issue. *Cancer Screen Prev* 2022;1(1):1–2. doi: 10.14218/CSP.2022.00000.

devices, and technologies related to various cancers, especially gastrointestinal cancer. Studies on the integration of precision cancer prevention multiomics, in which cancer screening, early detection and prevention regimens can precisely reflect the risk of cancer from dissected genomic and environmental parameters, are particularly welcome.

CSP is an open-access and peer-reviewed journal, and publishes articles that comply with the International Committee of Medical Journal Editors (ICMJE) recommendations, ensuring integrity and accuracy.<sup>4</sup>

The journal is published by Xia & He Publishing Inc. (XHP). At present, the editorial board consists of 102 worldwide qualified experts from 19 countries and regions, with an average H-index of 22, according to the data collected from Web of Science. We are confident that, with the favorable reputation and high dedication of XHP, and the strong support and contributions of the editorial board members, CSP will become an internationally influential

journal for cancer screening and prevention.

## References

- [1] Wei W, Zeng H, Zheng R, Zhang S, An L, Chen R, *et al*. Cancer registration in China and its role in cancer prevention and control. *Lancet Oncol* 2020;21(7):e342–e349. doi:10.1016/S1470-2045(20)30073-5, PMID:32615118.
- [2] Eight academicians' advocacy: early screening should be included in the national policy of cancer prevention. (Chinese) Available from: [https://www.sohu.com/a/365277121\\_796859](https://www.sohu.com/a/365277121_796859). Accessed November 15, 2022.
- [3] Cao M, Li H, Sun D, He S, Yan X, Yang F, *et al*. Current cancer burden in China: epidemiology, etiology, and prevention. *Cancer Biol Med* 2022;19(8):1121–1138. doi:10.20892/j.issn.2095-3941.2022.0231, PMID:36069534.
- [4] ICMJE. Available from: <https://www.icmje.org/recommendations/>. Accessed October 22, 2022.